Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.58 |
| ▸ | MTOR | P42345 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12312539 | 1.00 | TSHR (0.64) | TSHRHIF1AMEN1CYP1A2KMT2A | |
| SCHEMBL9183624 | 1.00 | TSHR (0.64) | TSHRHIF1AMEN1CYP1A2KMT2A | |
| Acetic Acid SCHEMBL11142923 | 0.93 | MEN1 (0.57) | TSHRHIF1AMEN1CYP1A2KMT2A | |
| SCHEMBL11144387 | 0.91 | ADRB3 (0.65) | TSHRHIF1AMEN1CYP1A2KMT2A | |
| Propionic Acid SCHEMBL11145356 | 0.89 | MEN1 (0.54) | TSHRHIF1AMEN1CYP1A2KMT2A | |
| SCHEMBL10685645 | 0.88 | KDM4E (0.63) | TSHRHIF1AMEN1CYP1A2KMT2A | |
| Pivalate SCHEMBL10878547 | 0.87 | BLM (0.51) | TSHRHIF1AMEN1CYP1A2KMT2A | |
| SCHEMBL14943968 | 0.86 | APAF1 (0.62) | MEN1CYP1A2KMT2ACYP2D6KDM4E | |
| SCHEMBL10879125 | 0.86 | APAF1 (0.62) | MEN1CYP1A2KMT2ACYP2D6KDM4E | |
| SCHEMBL10879127 | 0.86 | APAF1 (0.62) | MEN1CYP1A2KMT2ACYP2D6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3801510-B1 | COMPOUNDS INCREASING THE EXPRESSION OF SARCOSPAN FOR USE IN THE TREATMENT OF MUSCULAR DYSTROPHY | UNIV CALIFORNIA (US) | 2025-04-23 | — | — | EP | claimed |
| EP-0002638-B1 | ADDITION SALTS OF SUBSTITUTED ARALKYLAMINS AND THERAPEUTIC COMPOSITION CONTAINING THEM | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1982-01-20 | — | — | EP | claimed |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-06-01 | — | — | US | disclosed |
| EP-4173675-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | Perha Pharmaceuticals (FR) | 2023-05-03 | — | — | EP | disclosed |
| US-11286235-B2 | Ultra short acting anti-arrhythmic agents | Academic Pharmaceuticals, Incorporated (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3520779-B1 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20210107867-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | ACADEMIC PHARMACEUTICALS INCORPORATED | 2021-04-15 | — | — | US | disclosed |
| US-10793519-B2 | Ultra short acting anti-arrhythmic agents | ACADEMIC PHARMACEUTICALS INCORPORATED (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190352257-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | ACADEMIC PHARMACEUTICALS INCORPORATED | 2019-11-21 | — | — | US | disclosed |
| EP-3482775-A1 | 11C-LABELLED CATECHOL DERIVATIVE, POSITRON EMISSION TOMOGRAPHY (PET) PROBE FOR PHOSPHORYLATED TAU AGGREGATION INHIBITOR USING SAME, AND PRODUCTION METHODS THEREFOR | National Center for Geriatrics and Gerontology (JP) | 2019-05-15 | — | — | EP | disclosed |
| EP-2708225-B1 | DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin | CYDEX PHARMACEUTICALS INC (US) | 2018-12-26 | — | — | EP | disclosed |
| WO-2005104712-A2 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX, INC. (US) | 2005-11-10 | — | — | WO | disclosed |
| US-5412119-A | Method of preparing vicinal aminoalcohols | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1995-05-02 | — | — | US | disclosed |
| EP-0554933-A1 | Method of preparing vicinal aminoalcohols | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1993-08-11 | — | — | EP | disclosed |
| EP-0036426-A4 | NOVEL PROCESS AND INTERMEDIATES USEFUL IN THE PREPARATION OF SYMPATHOMIMETIC AMINES. | INTERX RESEARCH CORP (US) | 1983-03-29 | — | — | EP | disclosed |
| US-4372969-A | CENTRAL NERVOUS SYSTEM ANTIDEPRESSANTS | SOCIETE ANONYME DITE: LABORATOIRE L. LAFON (FR) | 1983-02-08 | — | — | US | disclosed |
| EP-0002638-B1 | ADDITION SALTS OF SUBSTITUTED ARALKYLAMINS AND THERAPEUTIC COMPOSITION CONTAINING THEM | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1982-01-20 | — | — | EP | disclosed |
| EP-0036426-A1 | NOVEL PROCESS AND INTERMEDIATES USEFUL IN THE PREPARATION OF SYMPATHOMIMETIC AMINES. | INTERX RESEARCH CORP (US) | 1981-09-30 | — | — | EP | disclosed |
| WO-1981000849-A1 | NOVEL PROCESS AND INTERMEDIATES USEFUL IN THE PREPARATION OF SYMPATHOMIMETIC AMINES | INTERX RESEARCH CORP (US) | 1981-04-02 | — | — | WO | disclosed |
| EP-0002638-A1 | Addition salts of substituted aralkylamins and therapeutic composition containing them | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1979-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352257-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | SCN5A, CACNA1G, CACNA1H | TSHR 1990/4885HIF1A 4864/4885MEN1 4352/4885 |
| US-20210107867-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | SCN5A, CACNA1G, CACNA1H | TSHR 1990/4885HIF1A 4864/4885MEN1 4352/4885 |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | CLK1, CLK2, CLK3 | TSHR 1968/4885HIF1A 1644/4885MEN1 1197/4885 |
| US-11286235-B2 | Ultra short acting anti-arrhythmic agents | SCN5A, CACNA1G, CACNA1H | TSHR 1990/4885HIF1A 4864/4885MEN1 4352/4885 |
| US-10793519-B2 | Ultra short acting anti-arrhythmic agents | SCN5A, CACNA1G, CACNA1H | TSHR 1990/4885HIF1A 4864/4885MEN1 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.